Groupama Asset Managment Buys Shares of 7,226 Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Groupama Asset Managment bought a new stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 7,226 shares of the medical equipment provider's stock, valued at approximately $762,000.

Other large investors have also modified their holdings of the company. Roman Butler Fullerton & Co. bought a new position in Zimmer Biomet during the 4th quarter worth approximately $473,000. Geode Capital Management LLC raised its position in shares of Zimmer Biomet by 2.6% during the 3rd quarter. Geode Capital Management LLC now owns 4,879,385 shares of the medical equipment provider's stock valued at $524,942,000 after acquiring an additional 125,852 shares in the last quarter. M&T Bank Corp lifted its stake in Zimmer Biomet by 48.4% during the third quarter. M&T Bank Corp now owns 26,719 shares of the medical equipment provider's stock worth $2,884,000 after purchasing an additional 8,709 shares during the last quarter. KLCM Advisors Inc. acquired a new position in Zimmer Biomet in the fourth quarter worth $7,825,000. Finally, Peddock Capital Advisors LLC bought a new stake in Zimmer Biomet during the fourth quarter valued at $654,000. Institutional investors own 88.89% of the company's stock.

Insiders Place Their Bets

In other news, SVP Lori Winkler sold 1,443 shares of the stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total value of $150,649.20. Following the completion of the sale, the senior vice president now directly owns 8,768 shares of the company's stock, valued at $915,379.20. This represents a 14.13 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.70% of the company's stock.

Remove Ads

Zimmer Biomet Trading Down 4.6 %

Shares of NYSE ZBH traded down $5.20 during mid-day trading on Friday, hitting $107.46. 3,852,949 shares of the company traded hands, compared to its average volume of 1,587,609. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43. Zimmer Biomet Holdings, Inc. has a 1 year low of $97.69 and a 1 year high of $129.50. The stock has a market capitalization of $21.39 billion, a price-to-earnings ratio of 24.15, a PEG ratio of 1.95 and a beta of 1.04. The business has a 50 day moving average of $107.32 and a two-hundred day moving average of $107.21.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, beating analysts' consensus estimates of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same quarter last year, the firm earned $2.20 earnings per share. On average, sell-side analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be paid a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 0.89%. The ex-dividend date is Monday, March 31st. Zimmer Biomet's dividend payout ratio is currently 21.57%.

Wall Street Analyst Weigh In

ZBH has been the subject of a number of recent research reports. JPMorgan Chase & Co. upgraded Zimmer Biomet from a "neutral" rating to an "overweight" rating and upped their price objective for the stock from $125.00 to $128.00 in a research note on Tuesday, December 17th. Truist Financial restated a "hold" rating and set a $113.00 price target (down previously from $118.00) on shares of Zimmer Biomet in a research report on Monday, February 10th. Needham & Company LLC reiterated a "hold" rating on shares of Zimmer Biomet in a research report on Friday, February 7th. Royal Bank of Canada decreased their target price on shares of Zimmer Biomet from $130.00 to $125.00 and set an "outperform" rating for the company in a research report on Friday, February 7th. Finally, JMP Securities reaffirmed a "market outperform" rating and set a $140.00 price target on shares of Zimmer Biomet in a report on Friday, February 7th. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have given a buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $124.15.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.